argenx SE ARGX
971.55 USD +9.28 (+0.96%)
At closeNov 11, 2026, 5:04 AM EST
969.34 -2.21 -0.23%
Pre-market · Nov 11, 5:04 AM ET
958.60 Day range 976.39
661.85 52-week range 1,072.75
- YTD
- +15.53%
- 1 year
- +11.69%
News
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX). Such investors are advised to contact…
benzinga.com If You Invested $100 In argenx Stock 5 Years Ago, You Would Have This Much Today argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 15.47% on an annualized basis producing an average annual return of 25.51%. Currently, argenx has a market capitalization of…
fool.com 3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade Argenx's Vyvgart franchise addresses about 28,000 patients today, with the company targeting 60,000 by 2030. The biotech is solidly profitable, with Q3 revenue up 54% and $3.7 billion in cash to fund…
benzinga.com Reported Saturday, argenx Plans To Submit Supplemental BLA For Efgartigimod In IMNM By End Of 2026 After Phase 3 ALKIVIA Shows 14.8-Point Greater TIS Improvement Versus Placebo At Week 52 ALKIVIA met its primary and key secondary endpoints in the combined IMNM and DM populationFirst Phase 3 study to demonstrate statistically significant and clinically meaningful benefit in IMNM, an…
benzinga.com Argenx To Acquire Unnatural Products For Up To ~$1.15B Including $550M Upfront And Up To $595M In Milestones, Adding Peptide Discovery Engine Pairs Unnatural Products’ (UNP) peptide expertise with argenx's antibody engineering, expanding the ways to target novel biology Extends argenx’s immunology innovation to more patients, with the…
globenewswire.com Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines Argenx to acquire UNP for $550 million upfront plus contingent value rights tied to development and regulatory milestones, for total potential value of up to approximately $1.15 billion
globenewswire.com argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities Amsterdam, the Netherlands, November 9, 2026, 07:00 CET – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced a definitive agreement to acquire Unnatural Products,…
globenewswire.com argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis ALKIVIA met its primary and key secondary endpoints in the combined IMNM and DM population First Phase 3 study to demonstrate statistically significant and clinically meaningful benefit in IMNM, an…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact…
zacks.com Best Biotech Stocks to Buy Now as AI Stocks Tank: ARGX Investors should consider buying resurgent healthcare and biotech stocks amid the AI selloff. Today, we are digging into why it might be time to buy biopharmaceutical stock Argenx (ARGX).
benzinga.com Citigroup Maintains Buy on argenx, Lowers Price Target to $1232 Citigroup analyst Samantha Semenkow maintains argenx (NASDAQ:ARGX) with a Buy and lowers the price target from $1301 to $1232.
benzinga.com $1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 12.9% on an annualized basis producing an average annual return of 23.66%. Currently, argenx has a market capitalization of…
benzinga.com Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $1190 Morgan Stanley analyst Sean Laaman maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1140 to $1190.- benzinga.com Guggenheim Maintains Buy on argenx, Lowers Price Target to $1120 Guggenheim analyst Yatin Suneja maintains argenx (NASDAQ:ARGX) with a Buy and lowers the price target from $1185 to $1120.
- benzinga.com Wells Fargo Maintains Overweight on argenx, Lowers Price Target to $1336 Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and lowers the price target from $1356 to $1336.
- benzinga.com Evercore ISI Group Maintains Outperform on argenx, Raises Price Target to $1090 Evercore ISI Group analyst Gavin Clark-Gartner maintains argenx (NASDAQ:ARGX) with a Outperform and raises the price target from $1078 to $1090.
benzinga.com Procter & Gamble To Rally Over 12%? Here Are 10 Top Analyst Forecasts For Friday Analysts cut EAT, TTMI and MRTN targets, while raising SPOT, RBLX, S, PG and ARGX; ratings were largely maintained.- benzinga.com Baird Maintains Neutral on argenx, Raises Price Target to $861 Baird analyst Colleen Kusy maintains argenx (NASDAQ:ARGX) with a Neutral and raises the price target from $823 to $861.
benzinga.com argenx Q3 2026 Earnings Call Transcript argenx (NASDAQ:ARGX) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com argenx Q3 EPS $7.80 Misses $7.83 Estimate, Sales $1.751B Beat $1.664B Estimate argenx (NASDAQ:ARGX) reported quarterly earnings of $7.80 per share which missed the analyst consensus estimate of $7.83 by 0.38 percent. This is a 50.58 percent increase over earnings of $5.18 per…
benzinga.com Procter & Gamble, Western Digital On Deck Thursday As Growth, AI Demand Face Test Procter & Gamble headlines Thursday’s reports, with investors weighing resilient consumer demand against cost pressures and softer earnings growth. Union Pacific, Lockheed Martin, Valero Energy and…
benzinga.com RBC Capital Maintains Outperform on argenx, Lowers Price Target to $1025 RBC Capital analyst Luca Issi maintains argenx (NASDAQ:ARGX) with a Outperform and lowers the price target from $1100 to $1025.- benzinga.com argenx SE To Present New Data From Phase 3 Study Evaluating VYVGART Hytrulo In Patients With Autoimmune Myositis, Focused On IMNM And DM, At ACR Convergence 2026 Results from the global Phase 3 ALKIVIA study, the first registrational study investigating an FcRn blocker in autoimmune myositis, show efgartigimod provides clinically meaningful improvements in…
- benzinga.com Wells Fargo Maintains Overweight on argenx, Raises Price Target to $1356 Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1355 to $1356.
- benzinga.com Oppenheimer Maintains Outperform on argenx, Lowers Price Target to $1038 Oppenheimer analyst Leland Gershell maintains argenx (NASDAQ:ARGX) with a Outperform and lowers the price target from $1100 to $1038.